Merit Medical Systems (MMSI) FDA Approvals $89.75 +0.71 (+0.80%) As of 04:00 PM Eastern Add Compare Share Share FDA Events Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Merit Medical Systems' Drug in the FDA Approval ProcessThis section highlights FDA-related milestones and regulatory updates for drugs developed by Merit Medical Systems (MMSI). Over the past two years, Merit Medical Systems has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as WRAPSODY. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. WRAPSODY FDA Regulatory Events WRAPSODY is a drug developed by Merit Medical Systems for the following indication: Cell-Impermeable Endoprosthesis (CIE). This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy. Enrollment Update - August 18,2025Enrollment Update Drug: WRAPSODYAnnounced Date: August 18, 2025Indication: Cell-Impermeable Endoprosthesis (CIE).AnnouncementMerit Medical Systems announced today the successful enrollment of the first patient in the WRAP North America registry.AI SummaryMerit Medical Systems announced the first patient enrollment in its WRAP North America registry. The study will gather safety and effectiveness data on the WRAPSODY CIE, which restores vascular access in hemodialysis patients with vein narrowing or blockage. Enrollment began at Bluff City Vascular in Memphis. The registry aims to enroll up to 250 patients in the U.S. and Canada, tracking outcomes over three years after treatment with the WRAPSODY CIE. Omar Davis, MD, Medical Director at Bluff City Vascular, said the registry offers a key opportunity to assess the device’s potential to optimize dialysis care. David J. Dexter II, MD, National Principal Investigator, said evaluating the WRAPSODY CIE’s performance will guide its broader clinical use. Merit CEO Fred P. Lampropoulos called the first enrollment an important step in building robust evidence and advancing technology to improve dialysis care.Read Announcement Merit Medical Systems FDA Events - Frequently Asked Questions Has Merit Medical Systems received FDA approval? As of now, Merit Medical Systems (MMSI) has not received any FDA approvals for its therapy in the last two years. What drugs has Merit Medical Systems submitted to the FDA? In the past two years, Merit Medical Systems (MMSI) has reported FDA regulatory activity for WRAPSODY. What is the most recent FDA event for Merit Medical Systems? The most recent FDA-related event for Merit Medical Systems occurred on August 18, 2025, involving WRAPSODY. The update was categorized as "Enrollment Update," with the company reporting: "Merit Medical Systems announced today the successful enrollment of the first patient in the WRAP North America registry." What conditions do Merit Medical Systems' current drugs treat? Currently, Merit Medical Systems has one therapy (WRAPSODY) targeting the following condition: Cell-Impermeable Endoprosthesis (CIE).. More FDA Event Resources from MarketBeat FDA Calendars Recent FDA Drug Approval Calendar Upcoming FDA Events & PDUFA Dates Calendar Companies With Recent FDA Events AbCellera Biologics FDA EventsAlumis FDA EventsAquestive Therapeutics FDA EventsArtelo Biosciences FDA EventsGrifols FDA EventsKodiak Sciences FDA EventsKura Oncology FDA EventsMoonLake Immunotherapeutics FDA EventsNeonc Technologies FDA EventsQuantum Biopharma FDA EventsSionna Therapeutics FDA EventsSilence Therapeutics FDA EventsTenax Therapeutics FDA EventsLabcorp FDA EventsQiagen FDA Events FDA Event Stage Terminology & Abbreviation Guide NDA: New Drug Application ANDA: Abbreviated New Drug Application sNDA: Supplemental New Drug Application BLA: Biologics License Application sBLA: Supplemental Biologics License Application FDA Approved: Approved by the FDA EMA: European Medicines Agency CE Mark: European Union Certification NMPA: China National Medical Products Administration MHLW: Japanese Ministry of Health FDA Meeting: Consultation with FDA Pre-IND: Pre-Investigational New Drug Meeting Breakthrough Therapy: Special FDA designation for promising therapies Fast Track: Accelerated FDA approval pathway Orphan Drug: Designation for rare disease treatments RPD: Rare Pediatric Disease Designation RMAT: Regenerative Medicine Advanced Therapy DSMB Review: Data Safety Monitoring Board Review IDMC Review: Independent Data Monitoring Committee MAA: MHRA Marketing Authorization Application RTF: Refusal to File (Rejected Application) 510(k): FDA Clearance for Medical Devices Rolling Submission: Staggered regulatory review process Related Companies Align Technology FDA Events QuidelOrtho FDA Events Sanara MedTech FDA Events Zimmer Biomet FDA Events Stock Lists Biotechnology StocksCompare Biotech StocksCompare Healthcare StocksCompare Pharmaceutical StocksHealthcare Stocks FDA progress for NASDAQ:MMSI last updated on 8/19/2025 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data. From Our PartnersHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredBofA: Digital Dollar Coming 2025-2030If you've got $50k+ sitting in a bank account, you need to hear this. There's a plan to merge every dollar you...Decentralized Masters | SponsoredBernie is gunning for your moneyBernie Sanders introduced a bill proposing a one-time 50% tax on shares of America's most successful companies...Porter & Company | SponsoredTrump's Next Move Could Shrink Your DollarThere's a plan in Washington being called the 'Mar-a-Lago Accord' - a deliberate strategy to weaken the U.S. d...Priority Gold | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored$8B is moving in... are you?Venture capital investment in US crypto companies hit $7.9 billion last year, up 44 percent from the year befo...Awesomely | SponsoredBarricks gold output fell from 2 million ounces to 719000Barrick's gold production has plunged from 2 million ounces to just 719,000, leaving the world's second-larges...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Merit Medical Systems, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Merit Medical Systems With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Enrollment Update - August 18,2025Enrollment Update Drug: WRAPSODYAnnounced Date: August 18, 2025Indication: Cell-Impermeable Endoprosthesis (CIE).AnnouncementMerit Medical Systems announced today the successful enrollment of the first patient in the WRAP North America registry.AI SummaryMerit Medical Systems announced the first patient enrollment in its WRAP North America registry. The study will gather safety and effectiveness data on the WRAPSODY CIE, which restores vascular access in hemodialysis patients with vein narrowing or blockage. Enrollment began at Bluff City Vascular in Memphis. The registry aims to enroll up to 250 patients in the U.S. and Canada, tracking outcomes over three years after treatment with the WRAPSODY CIE. Omar Davis, MD, Medical Director at Bluff City Vascular, said the registry offers a key opportunity to assess the device’s potential to optimize dialysis care. David J. Dexter II, MD, National Principal Investigator, said evaluating the WRAPSODY CIE’s performance will guide its broader clinical use. Merit CEO Fred P. Lampropoulos called the first enrollment an important step in building robust evidence and advancing technology to improve dialysis care.Read Announcement
